Day One Agenda

Please Note: Times Listed as EST | PST

Day One

Wednesday, December 7

Day Two

Thursday, December 8

8:00 am Registration & Virtual Networking

8:50 am Chair’s Opening Remarks

TIGIT Axis Targeted Therapies in Review

9:00 am SWOT Analysis Panel Discussion:

Synopsis

• What happened in the SKYSCRAPER trial?
• Progress, momentum and advancements one year on
• What are the strengths of existing TIGIT axis targeted therapies that continue to drive development?
• What is the market opportunity versus unmet patient clinical need that TIGIT axis targeted approaches can address?
• How can we overcome the high bar set by standard of care?
• What does the landscape of emerging and/or competing therapeutic approaches look like in this space?

Deciphering the TIGIT Axis at a Mechanistic Level & Optimizing Preclinical Models

9:30 am Revealing How the CD155/TIGIT Axis Plays a Critical Role in Pancreatic Cancer Immune Evasion

  • William Freed-Pastor Instructor of Medicine, Dana-Farber Cancer Institute & Harvard Medical School

Synopsis

• Novel preclinical models of neoantigen-expressing pancreas cancer uncover a key role for CD155/TIGIT
• CD155/TIGIT axis is sufficient to mediate immune evasion in PDAC
• TIGIT/PD-1 co-blockade plus CD40 agonism elicits robust anti-tumor activity in PDAC preclinical models

10:00 am Understanding the Complexity of CD226/TIGIT & CD96 for the Function of Tumor-Infiltrating T-Cells

  • Tobias Bald Group Leader of the Tumor Immuno-Biology Lab, University Hospital Bonn

Synopsis

• Exploring insights from single cell RNA sequencing in the head and neck cancer setting
• Deciphering the mechanistic reasons why TIGIT positive cells are not responding to TIGIT blockade

10:30 am Speed Networking Break

11:30 am Uncovering that TIGIT KO NK Cells Have Enhanced Cytotoxicity Against Lung Cancer Cells

  • Alicja Copik Associate Professor of Medicine, University of Central Florida

Synopsis

• Learning that TIGIT KO-NK cells kill tumor cells better as compared to WT NK cells
• Discussing the use of TIGIT KO NK cells as adoptive cell therapy alone or in combination with antibodies targeting TIGIT

12:00 pm Investigating New Combination Strategies Based on the Blockade of TIGIT to Increase Immune– Mediated Cytotoxicity in AML

  • Walter Fiedler Associate Professor, University Medical Center Hamburg-Eppendorf
  • Franziska Brauneck Assistant Physician, University Medical Center Hamburg-Eppendorf

Synopsis

• Evaluation of new targets for combination therapy with TIGIT to enhance T cell-mediated cytotoxicity in AML
• Dual checkpoint blockade for in vitro cytotoxicity assays
• Triple therapeutic approaches combining checkpoint blockade with metabolic targets for in vitro cytotoxicity assays
• Unleashing the innate immune system (including AML-associated macrophages and NK cells) by targeting TIGIT alone or in combination
• Repolarization and anti-leukemic phagocytosis of macrophages in vitro
• NK-cell mediated lysis of AML cells in vitr

12:30 pm Harnessing Spatial Approaches to Reveal TIGIT/PVR Axis & Improve Anti-PD1 Treatment in Gastrointestinal Cancer

Synopsis

• Using spatial analysis to identify the role of TIGIT/PVR within the tumor immune microenvironment
• Defining a combination strategy of TIGIT/PVR with PD-1/PD-L1 blockade

13:00 pm Lunch

Leveraging Biomarkers to Identify Patient Responders, Monitor Treatment & Delve Deeper into TIGIT Axis Targeted Drug MoA

Afternoon Chairperson

  • Leonie Meima Vice President Business Development, Coherus Biosciences

2:30 pm TIGIT: One Target with Multiple Ligands & Key Players

  • David Wald Associate Professor, Case Western Reserve University

Synopsis

• Providing an up-to-date review of key potential biomarkers
• Designing smarter trials using relevant biomarkers
• Utilizing new technologies to harness the power of key biomarkers

2:30 pm Exploring TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin’s Lymphoma

  • David Wald Associate Professor, Case Western Reserve University

Synopsis

• Demonstrating that TIGIT is induced on CAR-T cells after infusion into lymphoma patients
• Highlighting how TIGIT blockade can enhance the efficacy of CD19 CAR-T cells in animal models of human lymphoma

3:00 pm Afternoon Break

3:30 pm Sequential Single Cell Transcriptional & Protein Marker Profiling Reveals TIGIT as a Marker & Therapeutic Target to Enhance CD19 CAR-T Cell Therapy in Patients with Non-Hodgkin’s Lymphoma

Synopsis

• Exploring the role of TIGIT in CAR-T cells
• Investigating TIGIT and CD19 CAR-T cell combinatory therapy

4:00 pm Examining How Anti-TIGIT Antibody Tiragolumab Leverages Myeloid Cells & Regulatory T-Cells to Improve PD-L1 Checkpoint Blockade

Synopsis

• Biomarker data from early phase studies including a randomized phase 2 study
• Preclinical confirmatory studies that shed light on the potential mechanisms of TIGIT blockade

4:30 pm TIGIT is Main Immune Checkpoint on Tumor-Antigen Specific T Cells in HPV-Positive Head & Neck Cancer

Synopsis

  • Demonstration of a high throughput pipeline to detect tumor antigenspecific T-cells in patients
  • Highlighting the importance of TIGIT as a target in HPV-positive head and
    neck cancer

5:00 pm Chair’s Closing Remarks & Close of Day One

FULL AGENDA
PARTNER
REGISTER
NEXT PAGE: DAY TWO AGENDA